1. Home
  2. RGTI vs ERAS Comparison

RGTI vs ERAS Comparison

Compare RGTI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rigetti Computing Inc.

RGTI

Rigetti Computing Inc.

HOLD

Current Price

$20.53

Market Cap

5.9B

Sector

Technology

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$11.97

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGTI
ERAS
Founded
2013
2018
Country
United States
United States
Employees
164
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.5B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RGTI
ERAS
Price
$20.53
$11.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
12
Target Price
$30.78
$14.25
AVG Volume (30 Days)
51.1M
4.5M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
36.23
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$225.06
N/A
Revenue Next Year
$99.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.01
$1.24
52 Week High
$58.15
$24.28

Technical Indicators

Market Signals
Indicator
RGTI
ERAS
Relative Strength Index (RSI) 46.94 47.02
Support Level $14.51 $9.80
Resistance Level $27.16 $16.14
Average True Range (ATR) 2.64 0.98
MACD -0.15 0.36
Stochastic Oscillator 37.66 41.68

Price Performance

Historical Comparison
RGTI
ERAS

About RGTI Rigetti Computing Inc.

Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: